Le Lézard
Classified in: Health, Business
Subject: LIC

University of Iowa Health Care First to Adopt IDx-DR in a Diabetes Care Setting


CORALVILLE, Iowa, June 26, 2018 /PRNewswire/ -- IDx, a privately-held AI diagnostics company, announced today that University of Iowa Health Care is the first U.S. healthcare system to use IDx-DR, an AI diagnostic system that detects diabetic retinopathy, in a diabetes care setting.

AI diagnostic company IDx develops clinically-aligned autonomous algorithms to identify disease from medical images. It seeks to transform the quality, accessibility and affordability of healthcare by automating medical diagnosis and treatment. IDx expects FDA clearance determination for IDx-DR, an AI-based diagnostic system to detect diabetic retinopathy, in 2018. IDx is developing algorithms to detect macular degeneration, glaucoma, Alzheimer's disease, cardiovascular disease and stroke risk. (PRNewsfoto/IDx)

In April IDx-DR became the first autonomous AI diagnostic system cleared by the FDA ? meaning it uses artificial intelligence to make a diagnostic assessment without requiring a clinician to interpret the image or results. This enables healthcare providers who are not normally involved in eye care to test for diabetic retinopathy, a leading cause of blindness, during routine office visits.

Providers at the Diabetes and Endocrinology Center at UI Health Care?Iowa River Landing in Coralville, Iowa began using IDx-DR to assess patients for diabetic retinopathy on June 12. The clinic handles approximately 7,200 diabetes and endocrinology patient visits each year. After a successful launch at the UI Health Care?Iowa River Landing diabetes clinic, UI Health Care plans to expand the use of IDx-DR across the health care system.

"Early detection of diabetic retinopathy is an essential component of comprehensive diabetes care. This innovation further strengthens our ability to provide state-of-the-art care for our patients with diabetes," said E. Dale Abel, MD, PhD, director of the Division of Endocrinology and Metabolism at UI Health Care.

While IDx-DR is not intended to replace a comprehensive eye exam with an eye-care professional, it provides a convenient option for people with diabetes to complete their recommended annual diabetic retinopathy exam. This is particularly important for the more than 50 percent of people with diabetes who are at high risk for vision loss and do not see their eye doctor on a yearly basis.

In addition to the launch at UI Health Care, IDx is working on implementations at several other large healthcare systems who plan to go live with IDx-DR in 2018.

"The number of inquiries we've received from healthcare administrators and physicians since IDx-DR received clearance is remarkable," said Dr. Michael Abràmoff, founder and president of IDx. "This high level of interest shows how badly a solution like IDx-DR is needed to improve outcomes for people with diabetes. There is simply no reason for more than 24,000 individuals to lose vision each year from diabetic retinopathy."

IDx-DR is intended for use by healthcare providers to automatically detect more than mild diabetic retinopathy in adults (22 years of age or older) diagnosed with diabetes who have not been previously diagnosed with diabetic retinopathy. IDx-DR is indicated for use with the Topcon NW400.

About IDx, LLC
IDx is a leading AI diagnostics company on a mission to transform the quality, accessibility, and affordability of healthcare. Founded in 2010 by a team of world-renowned clinician scientists, the company is focused on developing clinically-aligned autonomous algorithms that detect disease in medical images. By enabling diagnostic assessment in primary care settings, IDx aims to increase patient access to high-quality, affordable disease detection.

The company's first product, IDx-DR, is an FDA-cleared AI-based diagnostic system designed for use at the front lines of care to detect diabetic retinopathy. IDx is developing additional AI-based diagnostic algorithms for the detection of macular degeneration, glaucoma, Alzheimer's disease, cardiovascular disease, and stroke risk. 

IDx, LLC
2300 Oakdale Blvd
Coralville, IA 52241
Phone:  319-248-5620
www.eyediagnosis.net

IDx Contact:
Laura Shoemaker
Director of Marketing Communications
1-319-248-5620
[email protected]

Media Contact:
Michelle Ronan Noteboom
Amendola Communications
1-512-426-2870
[email protected]

 

SOURCE IDx


These press releases may also interest you

at 03:28
Between 11 March 2024 and 15 March 2024 Concentric AB (LEI code 5493002G9GMTKIP3PW19) ("Concentric") has repurchased in total 21,812 own shares (ISIN: SE0003950864) as part of the repurchase program initiated by the Board. The repurchases form part...

at 03:09
Implantica AG (publ.), a medtech company at the forefront of bringing advanced technology into the body, announces the first-in-the-country public tender win for RefluxStoptm at Hospital Universitario de Getafe, a public hospital in Madrid, Spain....

at 03:00
Cypress HomeCare Solutions (Cypress), a legacy provider of in-home supportive care services, is excited to announce its selection of AxisCare as its enterprise software vendor. This strategic partnership highlights Cypress' commitment to enhancing...

at 03:00
Fusion Pharmaceuticals Inc. (Nasdaq:...

at 03:00
Following its successful entrance in Germany, Italy and Spain, Mintos, the multi-asset platform offering a unique mix of alternative and traditional investment options, continues its European rollout by making its official debut in the French and...

at 03:00
NAVEE, an emerging leader in the sharing e-scooter and e-bike industry, is set to showcase its latest products at the Autonomy Mobility World Expo 2024 in Paris from March 20-21. Renowned for highlighting sustainable urban transportation innovations,...



News published on and distributed by: